Last edition
News about
AusperBio Receives USD 37 Million in Series A Financing Round
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. has announced the completion of a USD 37 million Series A financing round.
Alembic Pharma Gets USFDA Tentative Approval for Selexipag for Injection
Alembic Pharmaceuticals has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial.
Moderna and Mitsubishi Tanabe Pharma to Promote mRNA Respiratory Vaccine in Japan
Moderna, Inc. has signed a joint agreement with Mitsubishi Tanabe Pharma regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
Nona Biosciences Signs Partnership Deal with Alaya.bio to Advance CAR-T Cell Therapy
Nona Biosciences has entered into a collaboration agreement with Alaya. bio to precisely target and reprogram cells in situ and thus to significantly simplify the way CAR-T cell therapies in particular are being developed, manufactured and administered.
BARDA and Tiba Biotech to Develop Innovative Therapeutics Against Influenza
Tiba Biotech has joined hands with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS).
Gericke Unveils GSF Lab System for Drug Development
Gericke has rolled out GFS LAB for continuous manufacturing of formulation development for drug development.
Dr. Reddy's Laboratories Launches Muslaxin in Russia
Dr. Reddy's Russia arm, part of the global pharmaceutical company Dr. Reddy’s Laboratories, has introduced Muslaxin (INN Ibuprofen 400 mg + Chlorzoxazone 500 mg), the first combination drug of NSAID and muscle relaxant that does not have generics in the Russian Federation.
ProofPilot Announces Closing of its Series C Funding
ProofPilot has announced the closing of its Series C financing, led by Sopris Capital with Mitsui & Co. (USA), Inc. participating.
AusperBio Gets BTD for AHB-137 in Chronic Hepatitis B Treatment
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. have announced that their investigational drug AHB-137 has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Nusano and PharmaLogic to Offer Current and Emerging Radiopharmaceuticals
Nusano Inc. has inked a supply agreement with PharmaLogic to provide a more efficient and reliable supply of critical radioisotopes.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy